Encoded Therapeutics is a biotechnology company advancing precision medicines for a broad range of genetic disorders.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/24/2021 | Series E | $378.09MM | $xx.xx | $212.78B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
16,631,476
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
07/22/2020 | Series D | $134.95MM | $xx.xx | $63.09B | Arch Venture Partners, Boxer Capital, Farallon Capital Management, Google Ventures, Hbm Genomics, Illumina Ventures, Matrix Capital Management, Menlo Ventures, Meritech Capital, Nolan Capital, Rtw Investments, Softbank Vision Fund 2 | |
Price per Share
$xx.xx
Shares Outstanding
16,078,670
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Boxer Capital, Farallon Capital Management, Google Ventures, Hbm Genomics, Illumina Ventures, Matrix Capital Management, Menlo Ventures, Meritech Capital, Nolan Capital, Rtw Investments, Softbank Vision Fund 2
|
||||||
06/26/2019 | Series C | $104MM | $xx.xx | $43.33B | Alexandria Venture Investments, Altitude Life Science Ventures, Arch Venture Partners, Boxer Capital, Illumina Ventures, Matrix Capital Management, Menlo Ventures, Rtw Investments, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
13,817,834
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Altitude Life Science Ventures, Arch Venture Partners, Boxer Capital, Illumina Ventures, Matrix Capital Management, Menlo Ventures, Rtw Investments, Venrock
|
||||||
12/31/2016 | Series B | $34.25MM | $xx.xx | $16.02B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
8,089,462
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
06/30/2016 | Series A | $15MM | $xx.xx | $3.89B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
10,901,157
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
12/31/2015 | Series Seed-1 | $1.09MM | $xx.xx | $1.08B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,099,248
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
12/31/2015 | Series Seed-2 | $3.5MM | $xx.xx | $1.08B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,391,246
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|